Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Research on life sciences described by M.R. Lassen and colleagues
August 3rd, 2009
"Significant progress has been made over the past decade in the development of new anticoagulants, as we have moved from unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), and warfarin to more target-specific inhibitors like direct and indirect factor Xa (FXa) inhibitors and direct thrombin inhibitors (DTIs). Warfarin and its congeners were for decades the sole available oral anticoagulants," scientists writing in the journal Thrombosis and Haemostasis report. "Fondaparinux, a specific FXa inhibitor approved for preventing venous thromboembolism (VTE) after elective total joint replacement and hip fracture surgery is, like UFH and LMWHs, a...
Source: Biotech Business Week (2009-08-03)
|
